Ipsen S.A. (EPA: IPN)
France flag France · Delayed Price · Currency is EUR
110.10
+2.50 (2.32%)
Nov 22, 2024, 5:35 PM CET

Ipsen Company Description

Ipsen S.A. operates as a biopharmaceutical company worldwide.

The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.

The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases.

The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Ipsen S.A.
Ipsen logo
Country France
Founded 1929
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 5,325
CEO David Loew

Contact Details

Address:
65, quai Georges Gorse
Boulogne-Billancourt, 92100
France
Phone 33 1 58 33 50 00
Website ipsen.com

Stock Details

Ticker Symbol IPN
Exchange Euronext Paris
Fiscal Year January - December
Reporting Currency EUR
ISIN Number FR0010259150
SIC Code 2834

Key Executives

Name Position
David Loew MD, Chief Executive Officer and Director
Aymeric Le Chatelier Executive Vice President and Chief Financial Officer
Dr. Aidan Murphy Ph.D. Executive Vice President and Head of Technical Operations
Craig Marks Vice-President of Investor Relations
Francois Garnier Executive Vice President of Legal Affairs, General Counsel and Chief Business Ethics Officer
Regis Mulot Executive Vice President and Chief Human Resources Officer
Dominique Bery Head of Nordics and Baltics
Bartosz Bednarz D.D.S. Executive Vice President and Head of Global Product and Portfolio Strategy
Philippe Lopes-Fernandes CBO Executive Vice President and Chief Business Officer
Dr. James Levine M.D., Ph.D. President of Fondation Ipsen